The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.

With the Biden administration pushing for Medicare, Medicaid coverage of GLP-1s, analysts disagree on whether it will ...

People struggling with their body weight experienced joy when new, more effective prescription drug options became the rage ...

A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) ...

Eli Lilly (LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug ...

Studies suggest that semaglutide reduces heart attack and stroke and may curb addiction and more. Scientists reflect on the future of GLP-1 drugs beyond weight loss.

Eli Lily continues to dominate the weight loss market, willing to crush any competitor that threatens its dominance. One such ...

The decision to limit Mounjaro injections to 220,000 people is ‘short-sighted and absurd’, says the former prime minister’s ...

We recently published a list of Jim Cramer’s Latest Calls: Top 10 Stocks. In this article, we are going to take a look at ...

It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news also continued to be in the spotlight.

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and acceptably safe for the treatment of type 2 diabetes and obesity, leading to ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, hope everyone is ...